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Liver ﬁbrosisPlatelet-derived growth factors (PDGFs) are critical for development; their over-expression is associated with
ﬁbrogenesis. Full-length PDGF-C is secreted as an inactive dimer, requiring cleavage to allow receptor binding.
Previous studies indicate that tissue-type plasminogen activator (tPA) is the speciﬁc protease that performs
this cleavage; in vivo conﬁrmation is lacking. We demonstrate that primary hepatocytes from tpa KO mice pro-
duce less cleaved active PDGF-CC than do wild type hepatocytes, suggesting that tPA is critical for in vitro activa-
tion of this growth factor. We developed mice that over-express full-length human PDGF-C in the liver; these
mice develop progressive liver ﬁbrosis. To test whether tPA is important for cleavage and activation of PDGF-C
in vivo, we intercrossed PDGF-C transgenic (Tg) and tpa knock-out (KO) mice, anticipating that lack of tPA
would result in decreased ﬁbrosis due to lack of hPDGF-C cleavage. To measure levels of cleaved, dimerized
PDGF-CC in sera, we developed an ELISA that speciﬁcally detects cleaved PDGF-CC. We report that the absence
of tpa does not affect the phenotype of `PDGF-C Tg mice. PDGF-C Tg mice lacking tPA have high serum levels of
cleaved growth factor, signiﬁcant liver ﬁbrosis, and gene expression alterations similar to those of PDGF-C Tg
mice with intact tPA. Furthermore, urokinase plasminogen activator and plasminogen activator inhibitor-1
expression are increased in PDGF-C Tg; tpa KO mice. Our ELISA data suggest a difference between in vitro and
in vivo activation of this growth factor, and ourmousemodel conﬁrms thatmultiple proteases cleave and activate
PDGF-C in vivo.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Tissue ﬁbrosis results from an imbalance in the metabolism of
extracellular matrix (ECM) proteins, and the plasminogen activation
system is a critical regulator of this balance [1–3]. Tissue plasminogen
activator (tPA) is a serine protease ﬁrst discovered via its ability to
cleave plasminogen to its active form, plasmin [1–4]. Given that tPAPA, tissue-type plasminogen ac-
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ights reserved.has a speciﬁc afﬁnity for ﬁbrin, its ability to activate plasminogen is
more restricted to areas of thrombosis than those of other plasminogen
activators. Mice deﬁcient in tPA develop and reproduce normally and
have a normal life span, though they display decreased thrombolytic
potential and increased endotoxin-induced thrombosis [5]. In the
liver, tPA appears to contribute to repair after injury [6], though
uninjured tpa knock-out (KO) mice have histologically normal livers
[5]. tPA, alongwith urokinase plasminogen activator (uPA) andplasmin,
is additionally important in the degradation of collagen [4]. The balance
of creation and degradation of collagen determines the composition of
the ECM of multiple organs, including the liver, and imbalance of
these systems can lead to organ ﬁbrosis. Increased activity of plasmino-
gen activator inhibitor-1 (PAI-1), which inhibits tPA and uPA function,
has been shown to lead to ﬁbrosis, for example [1]. The ECM of the
liver contains latent growth factors, which upon cleavage after injury
can lead to cell proliferation or inﬂammation, suggesting that the ﬁbri-
nolytic pathway could have additional functions in the ECM of the
liver, beyond collagen homeostasis.
The platelet-derived growth factor (PDGF) family has been exten-
sively studied over the past 40 years, and these ligands are required
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physiologic functions, as their overexpression results in a number
of pathological responses via mesenchymal cells, including liver ﬁbrosis
and cirrhosis [8–10]. PDGF-C and PDGF-D speciﬁcally are secreted as
latent factors, from which the complement subcomponents Clr/Cls,
Uegf, Bmp1 (CUB) domain must be cleaved to allow the active growth
factor dimers to bind their receptors [11,12]. Activated PDGF-CC binds
to either PDGFRα homodimers or PDGFRα/β heterodimers to initiate
intracellular signaling cascades, leading to diverse cellular processes
such as proliferation and migration. Upon the initial discovery of PDGF-
C, it was suggested that plasmin was the primary protease responsible
for cleavage of the CUB domain from the growth factor domain, thus
allowing downstream receptor activation [12]; a second group of investi-
gators demonstrated that this cleavage is serum-dependent [11]. Later
studies in ﬁbroblasts demonstrated that tPA has the ability to cleave
full-length PDGF-C to the active form [13–15]. Further, it has been
suggested that activation of latent PDGF-C by tPA in ischemic stroke is
responsible for the neurotoxic side effects of tPA in this setting; use of
imatinib, a kinase inhibitor whose targets include PDGFRs, has been
suggested for use in stroke patients to prevent this toxicity [15,16]. Direct
in vivo studies conﬁrming the relationship between tPA and PDGF-C
activation are lacking, however.
We have recently developed a mouse model in which liver ﬁbrosis,
angiogenesis, and tumor development are driven by hepatocyte-
speciﬁc over-expression of human PDGF-C [17]. Elevated serum levels
of cleaved, activated growth factor in these mice are associated with
up-regulation of pro-ﬁbrotic genes and liver ﬁbrosis that progresses
with age [17]. To maintain high levels of PDGF-CC, ongoing cleavage of
full length PDGF-C by an in situ protease or proteases is required. The
purpose of the current study was to determine whether tPA is indeed
the protease responsible for activation of PDGF-C in the liver in an
in vivo system. To this end, we intercrossed PDGF-C transgenic (Tg)
mice with those deﬁcient for tPA. Here we report that tPA appears
important for PDGF-C cleavage in vitro, including in primary hepato-
cytes, but in themore complex in vivo environment cleavage and activa-
tion of the growth factor occurs normally in the absence of tPA.
Moreover, PDGF-C Tg; tpa KO mice display a histologic phenotype
identical to that of PDGF-C Tg mice with intact tPA. Our ﬁndings suggest
that tPA is not the sole protease that is important for in vivo cleavage
and activation of PDGF-C, and that there is signiﬁcant redundancy
amongst PDGF-C-activating proteases.
2. Materials and methods
2.1. Enzyme-linked immunosorbent assay (ELISA) for determination of
PDGF-CC in serum
We use the following nomenclature for PDGF-C protein: PDGF-
C = non-cleaved, full-length protein including the growth factor do-
main and the CUB domain; PDGF-CC = cleaved, dimerized, activated
growth factor domain. Levels of PDGF-CC in media or mouse sera
were quantiﬁed using an antibody capture ELISA with two monoclonal
antibodies speciﬁc for human PDGF-CC, as described previously [11].
Other ligands tested to validate the speciﬁcity of the ELISA included
PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC and PDGF-DD (all from R&D),
as well as full-length (FL) PDGF-C and PDGF-CC isolated from
conditioned media derived from BHK cells overexpressing these two
constructs (indicated as ‘z’ since theywere developed at Zymogenetics)
[11].
2.2. Culture of primary hepatocytes and adenovirus infection
Primary hepatocytes were isolated by collagenase perfusion and
Percoll puriﬁcation from wild type and tpa KO mice and cultured as
previously described [18]. Primary hepatocytes were infected with ade-
noviruses over-expressing Lac-Z or full-length human PDGF-C [11] at anMOI of 2000; uninfected cells served as an additional control. Twenty-
four hours after infection, infectious media were washed off and
replaced with feeding media containing EGF (10 ng/ml). Three days
after plating, media were collected for detection of PDGF-CC using the
PDGF-CC speciﬁc ELISA; and hepatocytes were harvested for RNA
analysis as described below.
2.3. Animal studies
The generation and characterization of PDGF-C Tg mice have been
previously described [17]. PDGF-C Tg mice were crossed with mice
deﬁcient for tPA (Plattm1Mlg/J, Jackson Laboratories stock number
002508, referred to as tpaKO) to generatemicewith the four genotypes
used in study: wild type, tpa KO (lacking both tpa alleles), PDGF-C Tg,
and PDGF-C Tg; tpa KO (expressing the PDGF-C transgene and lacking
both tpa alleles). All mice were on the C57BL/6 background; mice
heterozygous for tpa were initially kept and examined, but as we did
not see any evidence of a gene dosage effect, tpa+/− mice were not
used in our ﬁnal analyses. Bromodeoxyuridine (BrdU, 50 μg/kg body
weight) was injected intraperitoneally (IP) 2 h prior to necropsy as de-
scribed [17,19]. At the indicated ages, mice were sacriﬁced by CO2 inha-
lation, sera collected by cardiac puncture, and livers and spleens
harvested, weighed, and ﬁxed or snap frozen for analysis. All animal
studies were carried out under approved Institutional Animal Care
and Use Committee protocols at the University of Washington.
2.4. Histology
Mouse livers were ﬁxed in 10% neutral buffered formalin or
Methacarn (60% methanol, 30% chloroform and 10% acetic acid: v/v/v)
overnight, processed to parafﬁn blocks, sectioned and stainedwith hema-
toxylin and eosin (H&E), picrosirius red, or trichrome using standard
techniques. Immunostainingwas performed onmethacarn ﬁxed sections
as described [17,19,20] using a primary antibody speciﬁc for BrdU (Dako,
Carpinteria, CA) and themouse onmouse kit (Vector Labs). Nuclear incor-
poration of BrdU into both hepatocytes and non-parenchymal cells
(NPCs) was used to measure cell proliferation; data are presented as the
number of BrdU positive hepatocyte nuclei or NPCs present in thirty
400× ﬁelds (1.3 mm2; approximately 3000 hepatocytes). Morphometric
analyses of liver ﬁbrosiswere performed on picrosirius red and trichrome
stained sections magniﬁed to 40× using a method similarly described
[21], using NIH Image J software.
2.5. RNA isolation and real-time PCR
Mouse livers or primary hepatocytes were harvested with
TRIzol Reagent (Invitrogen) per the manufacturer's protocol. 1 μg
of RNA template was used for reverse transcription by MMLV-RT
(Applied Biosystems, Carlsbad, CA) per the manufacturer's protocol.
50 ng of the resultant cDNA was subjected to real-time PCR analysis
using the following FAM labeled TaqMan primers (Applied Biosystems):
18s, Pdgfrα, Pdgfrβ, Col1a1, Col3, Col4a, Plat, Plau, and Serpine1; SYBR
Green-labeled primers were used to detect expression of human 18S
(Ambion, Life Technologies, Grand Island, NY) or PDGF-C (5′ ACAGAGGA
GGTAAGATTA TACAGC 3′, 5′ AATTGTGGAGACAACAGGCACAGT 3′). A
RotorGene 3000 thermocycler (Corbett Research, San Francisco, CA)
was used for detection, and the ΔΔCt method was used to calculate fold
change normalized to 18s or 18S [22].
2.6. Statistical analyses
Statistical analysis was done by non-parametric analysis using the
Mann-Whitney U t-test using GraphPad Prism software (GraphPad for
Science Inc., San Diego CA). Data are presented as average+/– S.E.M.,
with p b 0.05 (*) considered statistically signiﬁcant.
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3.1. Tpa KO hepatocytes have deﬁcient cleavage of PDGF-C
To determine whether the profound phenotype of PDGF-C Tg
mice was solely dependent on cleavage of PDGF-C by tPA, we ﬁrst
needed an assay that could speciﬁcally measure cleaved, active
PDGF-CC. We thus developed an ELISA for cleaved, activated PDGF-
CC that does not cross-react with other members of the PDGF family
(Fig. 1A). Using full-length (FL) and cleaved growth factor forms of
the C ligand at varying concentrations, we next demonstrated that
the ELISA is speciﬁc for the cleaved form, and does not cross-react
with the full-length secreted protein (Fig. 1B). Thus, PDGF-AA,
PDGF-AB, PDGF-BB, PDGF-DD, and FL-PDGF-C are undetectable by
this assay. Given prior in vitro data in ﬁbroblasts suggesting that
tPA is the protease responsible for cleavage of PDGF-C, prior to test-
ing our Tg mouse model, we wondered whether primary hepato-
cytes isolated from wild type and tpa KO would have an equivalent
ability to cleave PDGF-C. We infected these primary hepatocytes
with adenoviral vectors over-expressing human PDGF-C, LacZ, or a
scrambled control sequence. We subjected conditioned media from
infected hepatocytes to our speciﬁc ELISA, and found that tpa KO he-
patocytes had lower levels of cleaved active growth factor 3 days
after infection with Ad-PDGF-C than did wild type hepatocytes
(Fig. 1C). The decrease in protein levels does not appear to be due
to differences in adenoviral PDGF-C transduction in wild type and
tpa KO hepatocytes, as similar levels of hPDGF-C mRNA were detect-
ed in hepatocytes of each genotype (Fig. 1D). These in vitro studies
suggest that tPA does cleave PDGF-C in primary hepatocytes, corrob-
orating previous observations that tPA cleaves PDGF-C in ﬁbroblast
cultures [14].Fig. 1. A PDGF-CC speciﬁc ELISA demonstrates in vitro dependence on tPA for PDGF-C cleavage.
other PDGFs (A) or full length (FL) PDGF-C (B). PDGFs-AA, -AB, -BB, and -DD were not detecta
scribed [11] and are indicated by “z”, or purchased from R&D. We isolated wild type and tpa
ELISA measurements of cleaved, activated PDGF-CC in media from infected wild type and tpa
(by qPCR and normalized to 18S, D). Ad-Lac-Z infected and uninfected cells are shown as cont
in triplicate.3.2. PDGF-C Tg; t-PA KO mice are born at the expected frequency
Given the published evidence that tPA protease activity is critical for
cleavage and activation of PDGF-C in vitro, and our ﬁndings in primary
hepatocytes, we intercrossed tpa KO mice with mice over-expressing
hPDGF-C in the liver to examine the interaction between these two
proteins in vivo. Given that PDGF-C Tgmicewith intact tPA develop pro-
gressive liver ﬁbrosis [17], we reasoned that if the inactive full-length
PDGF-C dimer could not be cleaved by tPA, this phenotype would not
develop. We found that PDGF-C Tg; tpa KO mice develop and breed
normally, and do not have an overt phenotype other than expected
consequences of PDGF-Coverexpression. Supplementary Table 1 depicts
the birth frequencies of the progeny resulting from our crosses, and
demonstrates that PDGF-C Tg; tpa KOmice were born at the expected
Mendelian ratio.
3.3. PDGF-C Tg; tpa KO mice develop hepatomegaly, splenomegaly, and
cleave PDGF-C
PDGF-C over-expression drives enhanced proliferation of both hepa-
tocytes and NPCs in our Tg model, leading to hepatomegaly [17,19].
PDGF-C Tg mice also have splenomegaly, due to either parenchymal
proliferation or portal hypertension [17]. Fig. 2, panels A & B, demon-
strates that the increased size of these organs in PDGF-C Tg mice was
still present in the absence of tPA. If tPA was necessary for activation
of PDGF-C in vivo, we would expect this hyper-proliferative state to be
abolished in Tg animals lacking tPA. There were no differences between
liver and spleen size betweenwild type and tpa KOmice. Further, Fig. 2,
panels C & D, demonstrates equivalent BrdU incorporation in hepato-
cytes and NPCs of 6-month-old animals over-expressing PDGF-C with
or without tpa expression. We then performed the ELISA described inWe developed an ELISA speciﬁc for cleaved, active PDGF-CC; this ELISA does not recognize
ble by this assay. Ligands were puriﬁed from BHK over-expressing cells as previously de-
KO primary hepatocytes and infected them with adenoviruses over-expressing PDGF-C.
KO cells are shown (C). We achieved similarly high levels of PDGF-C expression in vitro
rols. * indicates p b 0.05. Data are representative of two separate experiments, each done
Fig. 2.Organ size, liver BrdU Incorporation, and PDGF-C cleavage in PDGF-C Tgmice do not depend on tPA.Weights of mouse whole liver (A) and spleen (B) relative to the bodyweight of
the animal at six months of age are shown. Liver sections from six-month-oldmice were stained with BrdU to assess cell proliferation in hepatocytes (C) and non-parenchymal cells (D).
BrdUpositive cellswere counted in thirty 400× ﬁelds for a total of 3000 cells evaluated (n = 6–12 per genotype). Serum levels of activated PDGF-CCwere determined in 1-month (E) and
6-month-old (F) wild type, tpa KO, PDGF-C Tg, and PDGF-C Tg; tpa KO mice, demonstrating that lack of tPA does not affect the circulating levels of activated PDGF-CC (n = 6–12 per
genotype at each age.).
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KO mice. Surprisingly, we found that PDGF-C Tg; tpa KO mice had
nearly identical levels of PDGF-CC in serum as did PDGF-C Tg mice
with intact tPA at one month (Fig. 2E) and six months (2 F) ofage, suggesting that tPA is not necessary for activating PDGF-C in
the liver. We hypothesize that in the complex in vivo environment,
more proteases may compensate for lack of tPA than in the simpli-
ﬁed cell culture environment, explaining the deﬁcit in growth
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PDGF-C is intact in the absence of tPA.
3.4. PDGF-C overexpression drives liver ﬁbrosis with or without tPA
We previously showed that hepatic over-expression of PDGF-C
results in pericellular and perivenular ﬁbrosis by 6 weeks of age,Fig. 3. PDGF-C-driven liver ﬁbrosis does not require tPA. Picrosirius red stainingwas used to asse
(C)mice at 3 months of age. Scale bar indicates 100 μm.Morphometric analysis of picrosirius re
mice (D). n = 3–4mice/genotype. Trichrome staining inwild type (E), PDGF-C Tg (F), and PDGF
indicates 50 μm.accompanied by increased peri-sinusoidal α-smooth muscle actin and
glial ﬁbrillary acidic protein expression [17]. H&E staining of liver
sections from PDGF-C Tg and PDGF-C Tg; tpa KOmice revealed a similar
pattern of liver architecture abnormalities (data not shown). We then
performed picrosirius red staining to speciﬁcally assess liver ﬁbrosis in
3-month-old PDGF-C Tgmicewith andwithout tPA.Minimal picrosirius
red staining was seen in wild type littermates, an example of which isss the development of liver ﬁbrosis inwild type (A), PDGF-C Tg (B), and PDGF-C Tg; tpa KO
d stained sections reveals equivalent amounts of ﬁbrosis in PDGF-C Tg vs PDGF-C Tg; tpaKO
-C Tg; tpaKO(G)mice conﬁrmed similar levels of ﬁbrosiswith orwithout tpa (H). Scale bar
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PDGF-C Tg mice with intact tpa have a moderate amount of ﬁbrosis at
this age (Fig. 3B), and that PDGF-C Tg; tpa KOmice (Fig. 3C) have ﬁbrosis
of qualitatively similar severity. To more precisely quantify ﬁbrosis in
PDGF-C Tg vs PDGF-C Tg; tpa KO mice, we additionally performed
morphometric analyses on these picrosirius red stained sections, and
found virtually identical amounts of ﬁbrosis in mice of these two
genotypes (Fig. 3D). To conﬁrm these results, we performed trichrome
staining at this same time point, and did not detect any signiﬁcant ﬁbro-
sis in wild type animals (Fig. 3E), nor did we detect a difference in the
amount of collagen deposition between PDGF-C Tg (Fig. 3F) and PDGF-
C Tg; tpa KO mice (Fig. 3G, quantiﬁed in H). We thus conclude that
PDGF-C Tg mice develop ﬁbrosis independent of tPA. Since we also de-
tect cleaved PDGF-CC in the absence of tPA, we hypothesize that there
are other proteases acting on the full-length ligand to cleave and acti-
vate PDGF-C.
3.5. Modulation of gene expression in PDGF-C Tg mice by tpa
The ﬁbrosis seen in PDGF-C Tg livers is preceded by up-regulation of
collagen gene expression. To determinewhether tPA activitymodulates
collagen expression in PDGF-C Tg mice, we performed qPCR for the col-
lagens Col1a1, Col3, and Col4 on RNA extracted from whole livers from
3-month-old wild type, tpa KO, PDGF-C Tg, and PDGF-C Tg; tpa KO
mice. As expected given the amount of ﬁbrosis in these animals, PDGF-
C Tg mice had marked induction of all three genes versus wild type or
tpa KO mice (Fig. 4A–C). Interestingly, Col1a1 and Col4 expression
were signiﬁcantly higher in PDGF-C Tg; tpa KO livers when compared
to PDGF-C Tg livers at this age, though there was no difference in Col3
expression with and without tPA. In our PDGF-C Tg mouse model, weFig. 4.Differential gene expression in PDGF-C Tg vs PDGF-C Tg; tpa KOmice. qPCRwas used to as
KO, PDGF-C Tg, and PDGF-C Tg; tpa KOmice at three months of age. Gene expression data were
mice. * indicates p b 0.05. n = 3–6 per genotype.have demonstrated that over-expression of PDGF-C leads to up-
regulation of expression of its receptor components, PDGFR-α and -β
(ref Fig. 4D, E). Using qPCR on the samples listed above, we found that
the absence of tPA did not affect expression of Pdgfrα, but slightly in-
creased expression of Pdgfrβ, in PDGF-C Tg mice. These data suggest
that tPA may subtly temper pro-ﬁbrotic signaling in PDGF-C Tg mice,
though we did not detect obvious differences in our histologic analyses
(Fig. 3).
Both tPA and uPA have the ability to convert plasminogen to its acti-
vated form, plasmin, while PAI-1 inhibits the activity of both of these
proteases [3]. Both proteases have anti-ﬁbrotic properties as well, and
wewonderedwhether expression of other components of this pathway
could compensate for the lack of tPA activity in PDGF-C Tg; tpa KOmice.
To evaluate how this pathway could be affected by over-expression of
PDGF-C and/or loss of tpa in the liver, we measured expression of
these genes in 3-month-old mice of our four genotypes by qPCR. We
found a marked up-regulation of the gene for tPA (Plat) in PDGF-C Tg
mice compared to wild type littermates, and additionally conﬁrmed
the complete absence of the gene for Plat expression in tpa KO and
PDGF-C Tg; tpa KO mice (Fig. 5A). Interestingly, both the gene for uPA
(Plau) and the gene for PAI1 (Serpine1) were up-regulated in PDGF-C
Tgmice, and expression of both of these genes was further signiﬁcantly
enhanced by the absence of tpa (Fig. 5B, C). These data suggest that uPA
could be compensating for loss of tPA activity in PDGF-C Tg; tpaKOmice,
and that themassive up-regulation of tPA and uPA in PDGF-C Tgmice is
associated with a concomitant increase expression of their endogenous
inhibitor, PAI-1. The latter fact may explain the absence of a signiﬁcant
difference in ECM deposition in PDGF-C Tg vs PDGF-C Tg; tpa KO mice
(Fig. 3) despite the observed differences in expression of genes for
collagens and PDGFRs (Fig. 4).sess expression of Col1a1 (A), Col3 (B), Col4 (C), Pdgfrα (D), and Pdgfrβ (E) inwild type, tpa
normalized to that of 18s, and graphed as fold change relative to expression in wild type
Fig. 5.Genes of the plasminogen cascade are increased in PDGF-C Tg; tpaKOmice. qPCRwas used to assess expression of the genes for tPA (Plat, A), uPA (Plau, B), and PAI-1 (Serpine1, C) in
three-month-oldwild type, tpa KO, PDGF-C Tg, and PDGF-C Tg; tpa KOmice. Gene expression datawere normalized to that of 18s, and graphed as fold change relative to expression inwild
type mice. * indicates p b 0.05. n = 3–6 per genotype.
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The main ﬁnding of the present study is that tPA is not essential
for cleavage and activation of PDGF-C in vivo. While we demon-
strated functional activation of PDGF-C by tPA in primary hepato-
cytes infected with adenoviruses over-expressing the inactive
growth factor (Fig. 1), corroborating prior work in vitro [13],
these ﬁndings were not replicated in our Tg mouse model. In fact,
mice that over-express PDGF-C in the liver in the absence of tPA
were phenotypically similar to those transgenic for PDGF-C alone
(Figs. 2–3). These data suggest that another protease (or prote-
ases) cleaves and activates PDGF-C in physiologic and pathologic
conditions in the liver. Previously published work suggested that
tPA is critical in activating PDGF-C to enhance blood–brain barrier
permeability [13,15,16]. At this time it is unclear whether the dif-
ference between our results and those of Su et al. relate to funda-
mental differences between the brain and the liver, or variability
in methods for measuring PDGF-CC and its activity in vivo.
We observed an interaction between tPA and PDGF-C in modu-
lating collagen gene expression (Fig. 4) in PDGF-C Tg mice. These
data are consistent with those of multiple other investigators,
which demonstrate that the ﬁbrinolytic pathway modulates the
development of ﬁbrosis in multiple organs, and the liver in partic-
ular. For instance, Hsiao et al. induced liver ﬁbrosis in wild type and
tpa KO mice with carbon tetrachloride, and found that tpa KO mice
had increased α-smooth muscle expression and more severe ﬁbro-
sis than did wild type mice. Contrary to these ﬁndings, Higazi et al.
performed similar experiments in upa and tpa KO mice, and found
that both strains of KO animals had decreased ﬁbrosis after chronic
carbon tetrachloride treatment [23]. In humans, circulating levels
of the receptor for uPA (uPAR) correlated with increasing stage of
liver ﬁbrosis in patients with hepatitis C virus [24], and another
group found that both uPA and soluble uPAR levels were elevated
in patients with cirrhosis, independent of etiology. Moreover,
soluble uPAR levels correlate with liver function and systemic
inﬂammation and have prognostic value for certain patients,
particularly those with alcoholic liver disease [25,26]. The mecha-
nisms by which plasminogen activators may modulate ﬁbrosis
include activation of matrix metalloproteinases [27], which de-
grade the ECM, and activation of protective growth factors such
as hepatocyte growth factor (HGF). Some authors have proposed
the use of plasminogen activators as anti-ﬁbrotic therapy, though
clinical data are lacking. Regardless, despite the elevation in colla-
gen gene expression in PDGF-C Tg; tpa KOmice vs Tg mice, we could
not detect a histologic difference in ﬁbrosis (Fig. 3), perhaps due to
the associated up-regulation of upa.Although previous studies indicated that tPA was the primary
protease responsible for PDGF-C cleavage [14,15], other studies sug-
gest redundancy in this proteolytic activity [11,12]. For instance in
MCF7 cells, a breast cancer cell line, uPA and matriptase have been
identiﬁed as proteases that can generate PDGF-CC, in addition to
tPA [28]. Another group studied activation of PDGF-C in the vitreous
humor of patients with proliferative vitreoretinopathy, and identi-
ﬁed plasmin as the primary PDGF-C-cleaving protease [29], similar
to the ﬁndings of the group of investigators who originally described
PDGF-C [12]. It is likely that multiple proteases are able to cleave and
activate PDGF-C, and that they are able to compensate for one anoth-
er when necessary. All of these cleavage events seem to require
Lys225 and/or Arg231, 234, which are located in the hinge region
between the growth factor domain and the CUB domain [30,28,11].
Interestingly, Eriksson's group recently demonstrated that uPA
appears to activate PDGF-D, and that uPA and its receptor uPAR
regulate the spatial distribution of this growth factor [31].
Mice deﬁcient for tPA were initially developed and character-
ized in the 1990s [5], and have normal development, life span,
and baseline histology of all organs, though their thrombolytic po-
tential is lower than that of wild type mice. Interestingly upa KO
mice develop spontaneous ﬁbrin deposits, whereas tpa KO mice
do not, and tpa KO mice do not have compensatory increased base-
line activity of other proteases (e.g. uPA). We found that in tpa KO
mice with the added stress of PDGF-CC induced liver ﬁbrosis, how-
ever, there was signiﬁcant compensatory up-regulation of upa
(Fig. 5), as well as Serpine1, the gene encoding PAI1, the primary
physiologic inhibitor of tPA and uPA. These data are in concert
with the notion that these two plasminogen activators are also
vital to the body's defenses against ﬁbrosis, and suggest that the
compensatory up-regulation of upa in PDGF-C Tg; tpa KO mice pre-
vents more severe liver ﬁbrosis in these animals. We suspect that a
PDGF-C Tg; upa KO mouse would have more severe ﬁbrosis, due to
the phenotype of upa KO mice compared to tpa KO mice [5].5. Conclusions
PDGF-C Tg; tpa KOmice have a phenotype nearly identical to that of
PDGF-C Tgmice, thus tPA is not necessary for cleavage and activation of
PDGF-C in the liver. Our ﬁndings suggest that multiple proteases are
able to cleave and activate PDGF-C, not exclusively tPA, and call into
question previous work on the interplay of these two proteins in health
and disease.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2013.11.013.
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